Methylmalonic aciduria microcephaly cataract

Methylmalonic Aciduria with Microcephaly and Cataract (MMAMC) is a rare genetic disorder characterized by the presence of methylmalonic acid in the urine, microcephaly (small head size), and cataracts in the eyes. This condition is part of a group of disorders known as organic acidemias, which involve an inability to properly metabolize certain amino acids and fats, leading to the accumulation of toxic substances in the body.

Causes

MMAMC is caused by mutations in specific genes that are involved in the metabolism of certain amino acids and fats. These genetic mutations lead to a deficiency in the activity of an enzyme necessary for the conversion of methylmalonyl-CoA to succinyl-CoA, a critical step in the breakdown of certain amino acids and fats. As a result, methylmalonic acid accumulates in the body, leading to the symptoms associated with the disorder.

Symptoms

The primary symptoms of MMAMC include:

• Methylmalonic aciduria: An increased level of methylmalonic acid in the urine.
• Microcephaly: A significantly smaller head size compared to others of the same age and sex.
• Cataracts: Clouding of the lens of the eye, leading to decreased vision.

Additional symptoms may include developmental delay, intellectual disability, and various metabolic complications.

Diagnosis

Diagnosis of MMAMC typically involves a combination of clinical evaluation, family history, and laboratory tests. These tests may include:

• Urine organic acid analysis to detect elevated levels of methylmalonic acid.
• Genetic testing to identify mutations in the genes associated with the disorder.
• Imaging studies to assess brain structure and size.

Treatment

There is no cure for MMAMC, and treatment focuses on managing symptoms and preventing metabolic crises. Treatment strategies may include:

• Dietary restrictions to limit the intake of certain amino acids.
• Supplementation with vitamins and cofactors, such as Vitamin B12 (cobalamin), which may help reduce methylmalonic acid levels in some patients.
• Regular monitoring of vision and early intervention for cataracts.

Prognosis

The prognosis for individuals with MMAMC varies depending on the severity of symptoms and the effectiveness of management strategies. Early diagnosis and treatment can improve the quality of life and reduce the risk of severe complications.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian